T. Rowe Price Associates’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $176M | Buy |
1,665,497
+264,759
| +19% | +$23.4M | 0.02% | 492 |
|
|
2025
Q4 | $122M | Buy |
1,400,738
+180,302
| +15% | +$14.8M | 0.01% | 589 |
|
|
2025
Q3 | $81.1M | Buy |
1,220,436
+283,733
| +30% | +$16.1M | 0.01% | 671 |
|
|
2025
Q2 | $51.8M | Sell |
936,703
-385,303
| -29% | -$18.5M | 0.01% | 725 |
|
|
2025
Q1 | $63.9M | Sell |
1,322,006
-70,646
| -5% | -$2.96M | 0.01% | 646 |
|
|
2024
Q4 | $53.8M | Buy |
1,392,652
+83,185
| +6% | +$3.63M | 0.01% | 730 |
|
|
2024
Q3 | $58.9M | Buy |
1,309,467
+99,925
| +8% | +$4.04M | 0.01% | 710 |
|
|
2024
Q2 | $41.9M | Buy |
1,209,542
+390,246
| +48% | +$11.4M | 0.01% | 775 |
|
|
2024
Q1 | $23.7M | Sell |
819,296
-4,444
| -0.5% | -$121K | ﹤0.01% | 938 |
|
|
2023
Q4 | $18.9M | Sell |
823,740
-8,253
| -1% | -$144K | ﹤0.01% | 973 |
|
|
2023
Q3 | $13.9M | Buy |
831,993
+300
| +0% | +$5.82K | ﹤0.01% | 1002 |
|
|
2023
Q2 | $23M | Buy |
831,693
+416,419
| +100% | +$10.4M | ﹤0.01% | 903 |
|
|
2023
Q1 | $9.55M | Buy |
+415,274
| New | +$6.97M | ﹤0.01% | 1063 |
|
|
2022
Q2 | – | Sell |
-300,468
| Closed | -$7.12M | – | 3003 |
|
|
2022
Q1 | $7.12M | Sell |
300,468
-76,664
| -20% | -$2.16M | ﹤0.01% | 1417 |
|
|
2021
Q4 | $12.9M | Sell |
377,132
-114,509
| -23% | -$3.62M | ﹤0.01% | 1369 |
|
|
2021
Q3 | $8.71M | Sell |
491,641
-494,613
| -50% | -$21.1M | ﹤0.01% | 1433 |
|
|
2021
Q2 | $44.3M | Buy |
986,254
+72,664
| +8% | +$2.4M | ﹤0.01% | 1069 |
|
|
2021
Q1 | $23.7M | Buy |
913,590
+68,195
| +8% | +$1.73M | ﹤0.01% | 1236 |
|
|
2020
Q4 | $17M | Buy |
845,395
+259,536
| +44% | +$5.59M | ﹤0.01% | 1254 |
|
|
2020
Q3 | $11.5M | Sell |
585,859
-161,775
| -22% | -$3.04M | ﹤0.01% | 1265 |
|
|
2020
Q2 | $13.2M | Buy |
747,634
+705,018
| +1,654% | +$8.85M | ﹤0.01% | 1242 |
|
|
2020
Q1 | $301K | Buy |
42,616
+100
| +0.2% | +$749 | ﹤0.01% | 2187 |
|
|
2019
Q4 | $300K | Buy |
42,516
+15,151
| +55% | +$150K | ﹤0.01% | 2315 |
|
|
2019
Q3 | $329K | Buy |
27,365
+7,879
| +40% | +$99.3K | ﹤0.01% | 2251 |
|
|
2019
Q2 | $236K | Buy |
19,486
+7,586
| +64% | +$83.9K | ﹤0.01% | 2368 |
|
|
2019
Q1 | $150K | Sell |
11,900
-9,200
| -44% | -$81.2K | ﹤0.01% | 2440 |
|
|
2018
Q4 | $142K | Buy |
21,100
+4,600
| +28% | +$36.5K | ﹤0.01% | 2457 |
|
|
2018
Q3 | $170K | Hold |
16,500
| – | – | ﹤0.01% | 2485 |
|
|
2018
Q2 | $111K | Sell |
16,500
-43
| -0.3% | -$330 | ﹤0.01% | 2517 |
|
|
2018
Q1 | $142K | Buy |
16,543
+6,722
| +68% | +$127K | ﹤0.01% | 2460 |
|
|
2017
Q4 | $204K | Buy |
+9,821
| New | +$174K | ﹤0.01% | 2417 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
T. Rowe Price Associates's PTGX Position: Q1 2026 in Review
T. Rowe Price Associates increased its Protagonist Therapeutics (PTGX) stake by 19% in Q1 2026, buying an estimated $23.4M and bringing the position to 1,665,497 shares worth $176M. The position accounts for 0.02% of the portfolio, ranked #492.
T. Rowe Price Associates first reported a position in PTGX in Q4 2017 and has held it in 31 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- T. Rowe Price Associates held 1,665,497 shares of Protagonist Therapeutics worth $176M as of Q1 2026.
- T. Rowe Price Associates bought 264,759 Protagonist Therapeutics shares in Q1 2026, an estimated $23.4M.
- Protagonist Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #492 holding.
- T. Rowe Price Associates first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 31 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.